NGNE biotech catalysts & pipeline

NEUROGENE INC · Data as of 2026-10-27

Upcoming catalysts

NGN-401 — Topline data

H2 2027

Completed successful dosing of 25 participants in Embolden; topline data anticipated in the second half of 2027

Source filing

NGN-401 — Conference presentation

Oct 27–Oct 30

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, will present data related to its NGN-401 gene therapy program for Rett syndrome at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress, taking place October 27-30, 2026, in Hamburg, Germany.

Source filing

Explore the free biotech catalyst calendar